

XUEYAN JIANG

Partner

Fangda Partners

+86 10 5769 5627

+86 139 1033 6081

xueyan.jiang@fangdalaw.com



PRACTICE AREAS

MS. JIANG XUEYAN IS A PARTNER AT THE BEIJING OFFICE OF FANGDA PARTNERS. MS. JIANG'S PRACTICE MAINLY FOCUSES ON THE ONSHORE AND OFFSHORE OFFERING AND LISTING OF SECURITIES, MERGERS, ACQUISITIONS AND REORGANIZATIONS IN CONNECTION WITH LISTED COMPANIES, PRIVATE EQUITY INVESTMENT AND FINANCING, ETC.

REPRESENTATIVE MATTERS AND CASES

Representative cases of onshore and offshore issuance of securities practiced by Ms. Jiang include:

- Represented, as the issuer's attorney, Bank of Chongqing (601963.SH), Xinyaqiang Silicon Chemistry (603155.SH), VeriSilicon (688521.SH), AMEC (688012.SH), Wuxi AppTec (603259.SH), Avary Holding (002938.SZ), Konruns Pharmaceutical (603590.SH) in their initial public offering and listing of A shares, and Air China (753.HK), Wuxi AppTec (2359.HK) in their initial public offering and listing of H shares, SDIC Power Holdings (600866.SH) in its GDR issuance and listing on the London Stock Exchange;
- Represented, as the sponsor or broker, Bio-Thera (688177.SH), Zelgen (688266.SH), Maxscend (300782.SZ), Foxconn Industrial Internet (601138.SH), Contemporary Ampere Technology (300750.SZ), Bank of Ningbo (002142.SZ) in their initial public offering and listing of A shares, and CSSC (3877.HK), CDB Leasing (1606.HK), Bank of Chongqing (1963.HK), China National Building Materials Group (3323.HK) in their initial public offering and listing in Hong Kong, Genetron Health (GTH.US) in its initial public offering and listing on NASDAQ;

- Represented, as the issuer's attorney, Wuxi AppTec (603259.SH/2359.HK) in its issuance of H-share convertible bonds, private placement of H shares and non-public offering of A shares, Sinopec (600028.SH/386.HK) in its private placement of H shares and issuance of H-share convertible bonds, A-share convertible bonds with warrants and A-share convertible bonds, Bank of Chongqing (1963.HK) in its private placement of H shares and issuance of offshore preferred shares, Shenzhen Kaifa Technology (000021.SZ) in its non-public offering of A shares, Bank of Ningbo (002142.SZ) in several non-public offerings of A shares and preferred shares and public offering of A-share convertible bonds, and Air China (601111.SH/753.HK) in its non-public offering of A shares;
- Represented the sponsor or broker, in the non-public offering of A shares by Maxscend Microelectronics (300782.SZ), Yiling Pharmaceutical (002603.SZ), Yibai Pharmaceutical (600594.SH), Bank of Beijing (601169.SH), the public offering of A-share convertible bonds and non-public offering of A shares by China Molybdenum Co., Ltd. (603993.SH/3993.HK), the issuance of H-share convertible bonds by CRRC Corporation (601766.SH/1766.HK), China Railway Construction Corporation (601186.SH/1186.HK), and the issuance of offshore preferred shares by Bank of Chongqing (1963.HK) and China Merchants Bank (3968.HK).

Representative cases of investment, financing, mergers and acquisitions, and joint venture practiced by Ms. Jiang:

- Represented Innoscience, Pactera, Data Interlink, Alpha Power, Marching Power, COFCO W&W, Cowealth Medical, Advanced Micro-Fabrication Equipment Inc., VeriSilicon, Wuxi AppTec, Avary Holding, JIC Leasing, Beijing Hebabiz Biotechnology Co., Ltd. as well as AutoAl and China Satellite Navigation and Communication Co., Ltd., MapBar, subordinated to Navinfo (002405.SZ) in the introduction of several investors;
- Represented China Integrated Circuit Industry Investment Fund Co., Ltd. ("IC Fund") in its investment of China Wafer Level CSP Co., Ltd. (603005.SH), Giga Device Semiconductor (Beijing) Inc. (603986.SH), Navtech Inc. (300456.SZ), Shenzhen State Micro Technology Co., Ltd. (02239.HK), Ninestar Corporation (002180.SZ), Centec Networks, Advanced Micro-Fabrication Equipment Inc.; Telink and Apex Microelectronics; represented Wuxi AppTec in its acquisition of Jiangsu Safe Pharmaceutical Co., Ltd., HD Biosciences Co., Ltd.; Dalian Elite Instruments, Blooming Spring, Changchun Biology and Milestone Pharma, in its acquisition of the minority equity in STA Pharma, a once NEEQ listed company, and its delisting, and its investments in Xinshiyuan Medical Technology, Chain Medical Labs, Cyagen and Gammastar; represented investors in their investment or acquisition of

INGEEK, CalmCar Vehicle Vision System, Zhejiang Shell, Medical, Ximalaya, Career International, Edianzu, Pantian Techonology, BYD Semiconductor, Hongfans Technology, Tongtuo Technology;

- Represented Guanjie Technology in the cash acquisition of its 51% shares by Huadong Electronics (000727.SZ) and the sale of all assets, Sichuan Haowu Electromechanical Co., Ltd. in its issuance of shares and payment of cashes for acquisition of Neijiang Pengxiang Investment Co., Ltd.; represented Sinopec in its mixed ownership reform of sales segments; represented Sinopec Yizheng Chemical Fibre Co., Ltd. (600871.SH/1033.HK) in its assets swap with Sinopec Oilfield Service Corporation; represented Sinopec in its acquisition of A-share listed companies, Sinopec Qilu Petrochemical Company Ltd., Sinopec Yangzi Petrochemical Co., Ltd., Sinopec Zhongyuan Petroleum Co., Ltd. and Sinopec Shengli Oil Field Dynamic Group Co., Ltd. by tender offer; represented Sinopec in its merger of H-share listed companies, Sinopec Beijing Yanhua Petrochemical Company Limited and Sinopec Zhenhai Refining & Chemical Company Limited;
- Represented CICC, IC Fund, Sinopec, Wuxi AppTec, VeriSilicon Microelectronics (Shanghai) Co., Ltd. and other companies in the establishment of joint ventures in respect of asset management, medical big data, manufacture and design of integrated circuit, together with their cooperators.

OTHER INFORMATION

Education

- Peking University School of Law, LL.M
- Peking University School of Law, LL.B

Professional Qualification

- Admitted to practice in the PRC

Honors and Awards

- Listed on the Capital Markets list of Chambers and IFLR1000 for several years

Professional Background

Prior to joining the Beijing Office of Fangda Partners, Ms. Jiang was a partner at a leading PRC law firm.